AMLX - NASDAQ

Amylyx Pharmaceuticals, Inc.

AMLX·NASDAQ

$13.61

+2.4%

HealthcareBiotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.13B

EPS-1.5300

P/E Ratio-8.89

Earnings Date08/06/2026

amlx

Other Current Assets

Last Annual Value

6.60M

3-Year CAGR

-13%

5-Year CAGR

10-Year CAGR

74%

Adjust for Inflation

Amylyx Pharmaceuticals, Inc. Competitors Analysis of Other Current Assets

AMLX · NASDAQ

Company	Other Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX	6.60M	-23.8%	13.9%	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	23.76M	92.8%	68.2%	N/A
Nektar Therapeutics NASDAQ:NKTR	0.00	N/A	N/A	N/A
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	63.26M	901.4%	198.9%	58.9%
Precigen, Inc. NASDAQ:PGEN	3.43M	-7.4%	-38.5%	-6.9%
Atai Beckley Inc. NASDAQ:ATAI	946.00K	3.8%	4.6%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	238.00K	-31.1%	-50.3%	-4.6%
Sana Biotechnology, Inc. NASDAQ:SANA	10.29M	7.4%	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	6.98M	16.5%	N/A	N/A

Amylyx Pharmaceuticals, Inc. Fair Value Envelope

AMLX · NASDAQ

Our analysis suggests that AMLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.605, this represents a potential HIDDEN relative to our calculated worth for Amylyx Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $13.605

Related Guides

Blog Categories

Continue your AMLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.